---
abstract: Cabotegravir (Apretude) is an extended-release injectable HIV type 1 (HIV-1)
  antiretroviral integrase strand transfer inhibitor. Cabotegravir is labeled for
  use in adults and adolescents weighing at least 35 kg (77 lb) who are HIV-negative
  but at risk of HIV-1. It is used as pre-exposure prophylaxis (PrEP) to reduce the
  risk of sexually acquired HIV-1 infection, the most common form of HIV.1.
authors:
- El-Haddad, Amer
- Erlich, Deborah
category: Clinical Review
clinical_significance: High
external_resources:
- title: PubMed Entry
  type: reference
  url: https://pubmed.ncbi.nlm.nih.gov/37192084/
file_path: 2023/05/cabotegravir-apretude-for-pre-exposure-prophylaxis-for-hiv-t.md
issue: '5'
keywords:
- HIV Infections
- Adolescent
- Pre-Exposure Prophylaxis
- Humans
- HIV-1
- Anti-Retroviral Agents
- Adult
- Pyridones
- Anti-HIV Agents
last_updated: '2025-07-30'
mesh_terms:
- Adult
- Adolescent
- Humans
- Pre-Exposure Prophylaxis
- HIV Infections
- Pyridones
- Anti-Retroviral Agents
- HIV-1
- Anti-HIV Agents
original_format: PubMed
pages: 545-546
patient_population: Pediatric
peer_reviewed: true
pmid: '37192084'
processed_date: '2025-07-30'
publication_date: '2023-05-01'
pubmed_enriched: true
pubmed_enriched_date: '2025-08-09'
reading_time_minutes: 5
source: American family physician
specialty:
- Family Medicine
status: processed
tags:
- clinical-review
- family-practice
- clinical-medicine
- pubmed-enhanced
title: Cabotegravir (Apretude) for Pre-exposure Prophylaxis for HIV Type 1 Infection.
topics:
- Family Medicine
volume: '107'
publication_types: &id001
- Journal Article
pubmed_content_enriched: true
pubmed_full_data:
  pmid: '37192084'
  title: Cabotegravir (Apretude) for Pre-exposure Prophylaxis for HIV Type 1 Infection.
  abstract:
    text: Cabotegravir (Apretude) is an extended-release injectable HIV type 1 (HIV-1)
      antiretroviral integrase strand transfer inhibitor. Cabotegravir is labeled
      for use in adults and adolescents weighing at least 35 kg (77 lb) who are HIV-negative
      but at risk of HIV-1. It is used as pre-exposure prophylaxis (PrEP) to reduce
      the risk of sexually acquired HIV-1 infection, the most common form of HIV.1.
  authors:
  - last_name: El-Haddad
    fore_name: Amer
    initials: A
    affiliation: Tufts University School of Medicine, Boston, Massachusetts.
  - last_name: Erlich
    fore_name: Deborah
    initials: D
    affiliation: Tufts University School of Medicine, Boston, Massachusetts.
  journal_info:
    title: American family physician
    iso_abbreviation: Am Fam Physician
    volume: '107'
    issue: '5'
  publication_info:
    year: '2023'
    month: '05'
    full_date: '2023-05-01'
  article_ids: {}
  mesh_terms:
  - descriptor: Adult
    major_topic: false
  - descriptor: Adolescent
    major_topic: false
  - descriptor: Humans
    major_topic: false
  - descriptor: Pre-Exposure Prophylaxis
    major_topic: true
  - descriptor: HIV Infections
    major_topic: true
    qualifiers:
    - qualifier: prevention & control
      major_topic: false
    - qualifier: drug therapy
      major_topic: false
  - descriptor: Pyridones
    major_topic: false
    qualifiers:
    - qualifier: therapeutic use
      major_topic: false
    - qualifier: pharmacology
      major_topic: false
  - descriptor: Anti-Retroviral Agents
    major_topic: false
    qualifiers:
    - qualifier: therapeutic use
      major_topic: false
  - descriptor: HIV-1
    major_topic: true
  - descriptor: Anti-HIV Agents
    major_topic: true
    qualifiers:
    - qualifier: therapeutic use
      major_topic: false
  publication_types: *id001
related_articles:
- pmid: '37192084'
  title: Cabotegravir (Apretude) for Pre-exposure Prophylaxis for HIV Type 1 Infection.
  authors:
  - name: El-Haddad A
    authtype: Author
    clusterid: ''
  - name: Erlich D
    authtype: Author
    clusterid: ''
  source: Am Fam Physician
  pubdate: 2023 May
- pmid: '36255686'
  title: 'Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure
    Prophylaxis.'
  authors:
  - name: Blair HA
    authtype: Author
    clusterid: ''
  source: Drugs
  pubdate: 2022 Sep
- pmid: '35894204'
  title: 'Cabotegravir: The first long-acting injectable for HIV pre-exposure prophylaxis.'
  authors:
  - name: Prather C
    authtype: Author
    clusterid: ''
  - name: Jeon C
    authtype: Author
    clusterid: ''
  source: Am J Health Syst Pharm
  pubdate: 2022 Oct 21
- pmid: '38648820'
  title: Considerations for Implementing Cabotegravir (Apretude) as PrEP for HIV Infection.
  authors:
  - name: Zimmerman H
    authtype: Author
    clusterid: ''
  - name: Vogl A
    authtype: Author
    clusterid: ''
  source: Am Fam Physician
  pubdate: 2024 Apr
- pmid: '30445896'
  title: 'Satisfaction and acceptability of cabotegravir long-acting injectable suspension
    for prevention of HIV: Patient perspectives from the ECLAIR trial.'
  authors:
  - name: Murray MI
    authtype: Author
    clusterid: ''
  - name: Markowitz M
    authtype: Author
    clusterid: ''
  - name: Frank I
    authtype: Author
    clusterid: ''
  - name: Grant RM
    authtype: Author
    clusterid: ''
  - name: Mayer KH
    authtype: Author
    clusterid: ''
  - name: Hudson KJ
    authtype: Author
    clusterid: ''
  - name: Stancil BS
    authtype: Author
    clusterid: ''
  - name: Ford SL
    authtype: Author
    clusterid: ''
  - name: Patel P
    authtype: Author
    clusterid: ''
  - name: Rinehart AR
    authtype: Author
    clusterid: ''
  - name: Spreen WR
    authtype: Author
    clusterid: ''
  - name: Margolis DA
    authtype: Author
    clusterid: ''
  source: HIV Clin Trials
  pubdate: 2018 Aug
---

# Cabotegravir (Apretude) for Pre-exposure Prophylaxis for HIV Type 1 Infection.

**Authors:** El-Haddad, Amer, Erlich, Deborah

**Published in:** American family physician | Vol. 107, No. 5 | 2023-05-01

**Links:** [PubMed](https://pubmed.ncbi.nlm.nih.gov/37192084/)

## Abstract

Cabotegravir (Apretude) is an extended-release injectable HIV type 1 (HIV-1) antiretroviral integrase strand transfer inhibitor. Cabotegravir is labeled for use in adults and adolescents weighing at least 35 kg (77 lb) who are HIV-negative but at risk of HIV-1. It is used as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection, the most common form of HIV.1.

## Clinical Information

**Population:** Pediatric | **Clinical Significance:** High

## Topics & Specialties

**Specialties:** Family Medicine

**Topics:** Family Medicine

## MeSH Terms

Adult, Adolescent, Humans, Pre-Exposure Prophylaxis, HIV Infections, Pyridones, Anti-Retroviral Agents, HIV-1, Anti-HIV Agents

## Article Content

*Full article content to be extracted and formatted from source material.*

## Additional Resources

- [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/37192084/) (reference)

---

*Processed: 2025-07-30* | *PubMed Enhanced: 2025-07-30*
